Pre-made Tanezumab biosimilar ( Whole mAb, anti-NGFB therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-549
Anti-NGFB therapeutic antibody (Pre-made Tanezumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-NGFB therapeutic antibody (Pre-made Tanezumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||4edw:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Back pain;Cancer pain;Musculoskeletal pain|
|Conditions Discontinued||Diabetic neuropathies;Postherpetic neuralgia|